Bio-Rad Laboratories, Inc. (BIO) fair value analysis
S&P 500 · Updated 2026-10-19
BIO price how computed
Forward Fair Value verdict
OvervaluedBIO is trading at a 10–25% premium to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $355.57
- Sector
- Healthcare
- 12-month range
- $241.71–$390.34
- Market cap
- $9.53B
- From 52-week high
- -8.9%
- Shares outstanding
- 26.8M
- Rank in Healthcare by discount to fair value
- #80 of 108
Last price is the 2026-10-01 month-start close, the freshest stored price; the chart runs through 2026-09-11.
Bio-Rad Laboratories, Inc. is a multinational manufacturer and distributor of life science research products, clinical diagnostics products, and related laboratory equipment. The company operates globally across North America, Europe, and other international markets, serving research institutions, clinical laboratories, and healthcare providers.
BIO currently ranks #80 of 108 Healthcare stocks by discount to fair value. It has screened as Overvalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $9.53B
- P/E (trailing)
- 38x
- Revenue (TTM)
- $2.59B
- Net margin
- 8.6%
- EPS (TTM)
- $9.28
- Gross margin
- 53.1%
- Debt / equity
- 0.17
- Revenue growth (3-yr avg)
- 1.0%
- Shares outstanding
- 26.8M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Stable
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 50 · neutral
- 50-day average
- $342.37
- 200-day average
- $303.31
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
What our data shows for BIO
- Our model validated 17 trailing price-to-earnings windows for BIO, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $241.71–$390.34.
- The 14-day relative strength index sits at a neutral 50.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for BIO
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent BIO news
TickrTrends' derived news-sentiment signal for BIO is currently leaning positive, computed from recent coverage.
- Bio-Rad Laboratories Inc (BIO) Stock Down 3.0% but Still Overvalued -- GF Score: 73/100 (gurufocus.com, 2026-10-16)
TickrTrends take: Bio-Rad Laboratories operates in the Healthcare sector where valuation multiples can fluctuate significantly based on product performance and market conditions. Despite the recent 3 percent stock decline, TickrTrends continues to assess the company as overvalued, suggesting that current price levels remain elevated relative to fundamental metrics even after the selloff. Investors focused on valuation should monitor whether further price adjustments occur or if the company's financial metrics shift to justify its current market position. - Bio-Rad Laboratories Inc (BIO) Shares Fall 5.9% -- What GF Score of 73 Tells Investors (gurufocus.com, 2026-10-01)
TickrTrends take: Bio-Rad Laboratories shares experienced a recent decline, which occurs against TickrTrends' current assessment that the stock trades at an overvalued level within the Healthcare sector. The company's GF Score of 73 suggests moderate fundamental quality, a metric that investors focused on valuation should weigh against the premium pricing TickrTrends has identified. For valuation-conscious investors, this combination of elevated price levels and a mid-range quality score represents a key tension point to monitor as the stock moves forward. - Bio-Rad Laboratories, Inc. at Bernstein Insights Healthcare Leaders and Disruptors Transcript (gurufocus.com, 2026-09-24)
TickrTrends take: Bio-Rad Laboratories, Inc. has been recognized at Bernstein Insights' Healthcare Leaders and Disruptors forum, indicating analyst attention to the company's strategic positioning within the Healthcare sector. Given TickrTrends' current assessment that BIO is overvalued, investors focused on valuation should monitor whether the company's operational performance and growth trajectory can justify its current market pricing or whether valuation multiples may compress. The recognition as a healthcare leader does not inherently resolve valuation concerns, making it important to track whether BIO can deliver earnings growth substantial enough to support its present valuation levels.
More BIO news
What people are saying
Follow the BIO conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for BIO showed a shift in the DCF cross-check band assessment this week, moving from an overvalued classification to none. The current valuation verdict remains overvalued overall. This change in the DCF cross-check band represents a notable adjustment in one component of the analytical framework, though the broader valuation assessment has stayed consistent.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is BIO stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), BIO is trading at a 10–25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.
What is BIO's TickrTrends verdict?
BIO's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.
How does BIO compare to other Healthcare stocks?
BIO ranks #80 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is BIO overbought or oversold?
BIO's 14-day RSI is in neutral territory - neither overbought nor oversold.
More in Healthcare
Head-to-head comparisons
BIO vs ABBV · BIO vs AMGN · BIO vs AZTA · BIO vs CNC · BIO vs DGX